Source:http://linkedlifedata.com/resource/pubmed/id/20144493
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2010-10-29
|
pubmed:abstractText |
Approximately 4% to 8% of patients with HIV-1 treated with abacavir present a hypersensitivity reaction (HSR). Various studies have shown a direct association between human leukocyte antigen (HLA)-B*5701 and HSR to abacavir. The objective of this study was to analyze whether systematic HLA-B*5701 testing to prevent HSR in patients treated with abacavir is a cost-effective option for the Spanish National Health System.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1578-1852
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright © 2009 Elsevier España, S.L. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
590-5
|
pubmed:meshHeading |
pubmed-meshheading:20144493-Anti-HIV Agents,
pubmed-meshheading:20144493-Cost-Benefit Analysis,
pubmed-meshheading:20144493-Dideoxynucleosides,
pubmed-meshheading:20144493-Drug Hypersensitivity,
pubmed-meshheading:20144493-HIV Seropositivity,
pubmed-meshheading:20144493-HLA-B Antigens,
pubmed-meshheading:20144493-Humans,
pubmed-meshheading:20144493-Models, Economic,
pubmed-meshheading:20144493-Spain
|
pubmed:year |
2010
|
pubmed:articleTitle |
Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.
|
pubmed:affiliation |
Oblikue Consulting, Barcelona, Spain. diana.nieves@oblikue.com
|
pubmed:publicationType |
Journal Article
|